Altshuler Shaham’s Protalix BioTherapeutics PLX Stock Holding History

Altshuler Shaham’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18K	Hold	7,742	–	–	﹤0.01%	292
2026 Q1	$16.8K	Sell	7,742 -4,400	-36%	-$10.9K	﹤0.01%	241
2025 Q4	$21.9K	Hold	12,142	–	–	﹤0.01%	230
2025 Q3	$27K	Hold	12,142	–	–	﹤0.01%	170
2025 Q2	$18K	Hold	12,142	–	–	﹤0.01%	196
2025 Q1	$31.1K	Hold	12,142	–	–	﹤0.01%	153
2024 Q4	$22.8K	Hold	12,142	–	–	﹤0.01%	207
2024 Q3	$12.4K	Hold	12,142	–	–	﹤0.01%	200
2024 Q2	$14.2K	Hold	12,142	–	–	﹤0.01%	202
2024 Q1	$15.3K	Hold	12,142	–	–	﹤0.01%	200
2023 Q4	$21.6K	Hold	12,142	–	–	﹤0.01%	188
2023 Q3	$20.2K	Hold	12,142	–	–	﹤0.01%	252
2023 Q2	$24.3K	Hold	12,142	–	–	﹤0.01%	267
2023 Q1	$25.5K	Sell	12,142 -336	-3%	-$589	﹤0.01%	297
2022 Q4	$17.1K	Buy	+12,478	New	+$13.7K	﹤0.01%	371

Other funds holding PLX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return

Altshuler Shaham's PLX Position: Q2 2026 in Review

Altshuler Shaham held its Protalix BioTherapeutics (PLX) position steady in Q2 2026 at 7,742 shares worth $18K. The position accounts for ﹤0.01% of the portfolio, ranked #292.

Altshuler Shaham first reported a position in PLX in Q4 2022 and has held it in 15 quarters since. The position peaked at $31.1K in Q1 2025. 73 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

Altshuler Shaham held 7,742 shares of Protalix BioTherapeutics worth $18K as of Q2 2026.
Altshuler Shaham left its Protalix BioTherapeutics share count unchanged in Q2 2026.
Protalix BioTherapeutics made up ﹤0.01% of Altshuler Shaham's portfolio in Q2 2026, its #292 holding.
Altshuler Shaham first reported a position in Protalix BioTherapeutics in Q4 2022 and has held it in 15 quarters since.
Altshuler Shaham's Protalix BioTherapeutics position peaked at $31.1K in Q1 2025.
73 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Altshuler Shaham's 13F filing for Q2 2026, filed 12 Aug 2026.